FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 01/2024 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 01/2024”. The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.

As of the end of January 2024 we identify the following current VC trends in Europe:

1. Total Healthcare & Life Sciences funding reached EUR 1,087m,a significant uptake from January of last year (EUR 1,087m vs. EUR 576m) 📈
2. Biotech received 62% of the total investment volume (EUR 675m) with oncology being the leading indication (46%)
3. In January Apollo Therapeutics (United Kingdom) secures the highest transaction volume with EUR 238m, followed by Calluna Pharma (Norway) with EUR 75m and Timeline (Switzerland) with EUR 60m
4. M&G Investments (United Kingdom) is the most active investor (by deal volume), followed by Patient Square Capital (United States) and Rock Springs Capital (United States)

To access the full report, please click here.